Page 45 - Read Online

Bittoni et al. J Cancer Metastasis Treat 2018;4:55 I http://dx.doi.org/10.20517/2394-4722.2018.37 Page 13 of 14

20. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, et al. Mutations associated with acquired resistance to pd-1 blockade in
melanoma. N Engl J Med 2016;375:819-29.
21. Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, et al. Primary resistance to PD-1 blockade mediated by JAK1/2
mutations. Cancer Discov 2017;7:188-201.
22. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade.
Science 2017;357:409-13.
23. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 2002;3:999-1005.
24. Brzostek J, Gascoigne NR, Rybakin V. Cell type-specific regulation of immunological synapse dynamics by B7 ligand recognition. Front
Immunol 2016;7:24.
25. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, et al. The immune score as a new possible approach for the classification of
cancer. J Transl Med 2012;10:1.
26. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, et al. Cancer classification using the immunoscore: a worldwide task force. J Transl
Med 2012;10:205.
27. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, et al. The consensus molecular subtypes of colorectal cancer. Nat Med
2015;21:1350-6.
28. Becht E, de Reyniès A, Giraldo NA, Pilati C, Buttard B, et al. Immune and stromal classification of colorectal cancer is associated with
molecular subtypes and relevant for precision immunotherapy. Clin Cancer Res 2016;22:4057-66.
29. Isella C, Brundu F, Bellomo SE, Galimi F, Zanella E, et al. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel
clinically relevant subtypes of colorectal cancer. Nat Commun 2017;8:15107.
30. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, et al. The vigorous immune microenvironment of microsatellite instable colon
cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015;5:43-51.
31. Verhagen J, Sabatos CA, Wraith DC. The role of CTLA-4 in immune regulation. Immunol Lett 2008;115:73-4.
32. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J ClinOncol
2016;39:98-106.
33. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
Science 2001;291:319-22.
34. Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in immunity and diseases. Curr Top Microbiol Immunol 2017;410:75-97.
35. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med
2015;372:2509-20.
36. Andre T, Lonardi S, Wong M, Lenz HJ, Gelsomino F, et al. Nivolumab + ipilimumab combination in patients with DNA mismatch
repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): first report of the full cohort from
CheckMate-142. J Clin Oncol 2018; doi: 10.1200/JCO.2018.36.4_suppl.553.
37. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA
mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018;36:773-9.
38. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, et al. Combined nivolumab and ipilimumab or monotherapy in untreated
melanoma. N Engl J Med 2015;373:23-34.
39. Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in
tumors. J Exp Med 2015;212:139-48.
40. Limagne E, Euvrard R, Thibaudin M, Rébé C, Derangère V, et al. Accumulation of MDSC and Th17 cells in patients with metastatic
colorectal cancer predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen. Cancer Res 2016;76:5241-52.
41. Triplett TA, Tucker CG, Triplett KC, Alderman Z, Sun L, et al. STAT3 signaling is required for optimal regression of large established
tumors in mice treated with anti-OX40 and TGFβ receptor blockade. Cancer Immunol Res. 2015;3:526-35.
42. Schaer D, Li Y, Castaneda S, Inigo I, Surguladze D, et al. Targeting the TGF pathway with galunisertib, a TGF-RI SMI, promotes anti-tumor
immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. J Immunother Cancer
2015;3:P402.
43. Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, et al. Immunosurveillance is active in colorectal cancer as downregulation but not
complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 2006;118:6-10.
44. Lal N, White BS, Goussous G, Pickles O, Mason MJ, et al. KRAS mutation and consensus molecular subtypes 2 and 3 are independently
associated with reduced immune infiltration and reactivity in colorectal cancer. Clin Cancer Res 2018;24:224-33.
45. Ebert PJR, Cheung J, Yang Y, McNamara E, Hong R, et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination
with PD-L1 checkpoint blockade. Immunity 2016;44:609-21.
46. Bendell JC, Bang YJ, Chee CE, Ryan DP, McRee AJ, et al. A phase Ib study of safety and clinical activity of atezolizumab (A) and
cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2018; doi: 10.1200/JCO.2018.36.4_suppl.560.
47. Chen N, Fang W, Zhan J, Hong S, Tang Y, et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven
NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol 2015;10:910-23.
48. Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted
IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-
based immunocytokines. Oncoimmunology 2017;6:e1277306.
49. Tabernero J, Melero I, Ros W, Argiles G, Marabelle A, et al. Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell
bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients
with metastatic colorectal cancer (mCRC). J Clin Oncol 2017; doi: 10.1200/JCO.2017.35.15_suppl.3002.
50. Segal NH, Kemeny NE, Cercek A, Reidy DL, Raasch PJ, et al. Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem)
plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients. J Clin Oncol 2016;